Download PDF

1. Company Snapshot

1.a. Company Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.


Fulcrum Therapeutics, Inc.has research and discovery collaboration agreement with Acceleron Pharma Inc.to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc.


to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.Fulcrum Therapeutics, Inc.was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on FULC

Fulcrum Therapeutics' recent performance was negatively impacted by the lack of significant clinical data updates. The company's announcement that it is on track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025, while positive, did not materialize during the recent quarter. Additionally, the company's recent inducement grants to new employees, while a positive sign of growth, may not have had a significant impact on the company's short-term performance.

1.c. Company Highlights

2. Fulcrum Therapeutics Q1 2026 Earnings: Clinical Wins Amid Cash‑Rich Balance

Fulcrum’s first‑quarter 2026 results reveal a company still burning cash but moving toward a viable product pipeline. Revenues were $0, reflecting the absence of commercial sales, while research and development expenses hit $14.1 million and general & administrative costs reached $8.1 million, culminating in a net loss of $22.2 million. Earnings per share stood at –$0.25, better than the consensus estimate of –$0.31. Cash, cash equivalents, and marketable securities topped $333.3 million, giving the firm a runway that extends well into 2029. Market valuation metrics illustrate the current discount: a P/E of –7.73 and a P/B of 1.77, indicating that the stock trades below book value but is still priced on a loss‑bearing basis.

Publication Date: Apr -28

📋 Highlights
  • Clinical Efficacy: Pociredir increased fetal hemoglobin (HbF) from 7.1% to 19.3% over 12 weeks in Phase Ib trial.
  • Financial Position: Net loss of $22.2M in Q1 2026, with $333.3M in cash reserves providing runway through 2029.
  • Competitive Edge: 24-month lead over BMS’s next oral HBF inducer, leveraging upstream disease-targeting mechanism.
  • Long-Term Safety: Open-label extension study initiated to evaluate sustained HbF, hemolysis, and hemoglobin improvements.
  • Regulatory Milestone: Planning end-of-phase FDA meeting to advance pociredir’s development pathway.

Clinical Progress

Phase Ib PIONEER data for pociredir (pociredir) in sickle cell disease are encouraging. A once‑daily 20 mg dose over 12 weeks produced a striking jump in fetal hemoglobin from 7.1% at baseline to 19.3% at week 12, accompanied by reductions in hemolysis markers and anemia. Moreover, 7 of 12 patients avoided vaso‑occlusive crises during the trial. The company has launched an open‑label, long‑term extension, enrolling its first patient to assess durability of HBF elevation and safety over extended exposure.

Strategic Developments

Fulcrum strengthened its governance by adding Josh Lehrer to the Board of Directors, while Alan Musso announced a planned retirement with a seamless transition. The company will engage the EMA later this year as part of its global rollout, and it is actively pursuing second‑through‑fourth‑generation oral HBF inducers that could further enhance efficacy or cannibalize pociredir in the future. CEO Alex Sapir noted the firm’s readiness to advance pociredir through the next phase of development, with an upcoming end‑of‑phase meeting with the FDA to refine trial design.[1]

Competitive Landscape

Fulcrum claims a 24‑month lead over the nearest competitor, BMS’s oral HBF inducer, citing its upstream mechanism of action that directly targets the disease root cause. The company is also exploring combination strategies with PKR activators or hydroxyurea, although its primary objective remains generating a robust monotherapy data set for pociredir. These positioning efforts aim to cement pociredir as the preferred once‑daily oral therapy in sickle cell disease.

Future Outlook

3. NewsRoom

Card image cap

Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call Transcript

Apr -27

Source: seekingalpha.com

Card image cap

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Apr -27

Source: globenewswire.com

Card image cap

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Apr -27

Source: globenewswire.com

Card image cap

Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors

Apr -27

Source: globenewswire.com

Card image cap

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET

Apr -20

Source: globenewswire.com

Card image cap

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Brokerages

Apr -04

Source: defenseworld.net

Card image cap

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

Mar -19

Source: globenewswire.com

Card image cap

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Moderate Buy” by Analysts

Mar -10

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Biopharmaceutical

Expected Growth: 10.43%

Fulcrum Therapeutics' 10.43% growth in biopharmaceuticals is driven by increasing demand for rare genetic disorder treatments, strategic partnerships, and a strong pipeline of novel therapies. The company's focus on gene regulation and epigenetics is also contributing to its growth, as well as its ability to leverage AI and machine learning in drug discovery.

7. Detailed Products

Fulcrum's FTX-6058

FTX-6058 is a small molecule designed to increase the expression of FUS, a protein that is deficient in individuals with FSHD.

Fulcrum's Losmapimod

Losmapimod is a p38α/β inhibitor that has been shown to reduce inflammation and improve muscle function in patients with FSHD.

Fulcrum's FTX-020

FTX-020 is a small molecule designed to increase the expression of a key protein involved in the regulation of muscle function.

Fulcrum's Gene Therapy Programs

Fulcrum's gene therapy programs are designed to treat genetic disorders by delivering a healthy copy of a gene to cells.

8. Fulcrum Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Fulcrum Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.

Bargaining Power Of Customers

Fulcrum Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Fulcrum Therapeutics, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size, the suppliers also have some leverage due to the specialized nature of their products.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. These barriers make it difficult for new entrants to enter the market.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Fulcrum Therapeutics, Inc. faces intense competition from companies with similar products and technologies.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 4.40%
Debt Cost 3.95%
Equity Weight 95.60%
Equity Cost 15.68%
WACC 15.16%
Leverage 4.60%

11. Quality Control: Fulcrum Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Rigel Pharma

A-Score: 5.7/10

Value: 5.9

Growth: 8.0

Quality: 9.3

Yield: 0.0

Momentum: 9.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Fulcrum Therapeutics

A-Score: 4.9/10

Value: 6.4

Growth: 8.0

Quality: 4.6

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Assembly Biosciences

A-Score: 4.5/10

Value: 6.0

Growth: 3.8

Quality: 4.6

Yield: 0.0

Momentum: 10.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
EyePoint Pharmaceuticals

A-Score: 4.0/10

Value: 6.2

Growth: 2.2

Quality: 4.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Lipocine

A-Score: 3.8/10

Value: 7.7

Growth: 6.8

Quality: 2.7

Yield: 0.0

Momentum: 3.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Clearside Biomedical

A-Score: 3.3/10

Value: 9.4

Growth: 3.6

Quality: 6.1

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

7.02$

Current Price

7.02$

Potential

-0.00%

Expected Cash-Flows